AzTrials
AzTrials

Ileostomy - StomaNCT05200416

Investigation of Heylo, a Novel App Driven Digital Supporting Ostomy Product

A study testing Heylo in people with Ileostomy - Stoma and Colostomy Stoma, run by Coloplast A/S at 1 site in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

People with intestinal stomas can have, despite development of better ostomy products, problems with leakage which influence their quality of life negatively. To overcome this, Coloplast has developed a new supporting ostomy product called Heylo™, which has an adhesive sensor layer that should be placed underneath the… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ileostomy - Stoma, Colostomy Stoma
What is being tested?
Heylo
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
144 participants
Where
1 siteGermany
Study dates
13 Jan 2022to 4 Nov 2022
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Has given written consent to participate by signing the Informed Consent Signature Form.
  • Is at least 18 years of age and has full legal capacity.
  • Has an ileostomy or colostomy with consistent liquid/mushy fecal output (5-7 Bristol scale*)
  • Is able to use one of the five test products (i.e. Ø40, Ø50, Ø60, Ø70, Ø80 mm).
  • Has experienced leakage under the baseplate at least three times within the last fourteen days. Leakage defined as output seeping under the baseplate"
  • Has worry about leakage to "some degree, high degree, or very high degree" (on a five-point Likert scale: Very low degree/Not at all, Low degree, some degree, High degree, very high degree)
Show all 9Show fewer
  • Is willing to refrain from use of ostomy paste.
  • Has a smartphone compatible with the Heylo™ application
  • Is able to follow study procedures for 4 months (assessed by investigator or delegate)

Who cannot join

  • Is participating in other clinical investigations or has previously participated in this investigation
  • Is pregnant or breastfeeding
  • Has known hypersensitivity towards any of the products used in the investigation
  • Is using/ has a pacemaker

Trial locations and contacts

1 site in 1 country.

Germany1 site
  • Peter C. Ambe

    Bergisch Gladbach, Bergisch Gladbach,Nordrhein-Westfalen, 51429

Other trials in Germany

About this study

Official title: A Randomized Cross-over Trial Investigating Heylo, a Novel App Driven Digital Supporting Ostomy Product

People with intestinal stomas can have, despite development of better ostomy products, problems with leakage which influence their quality of life negatively.

To overcome this, Coloplast has developed a new supporting ostomy product called Heylo™, which has an adhesive sensor layer that should be placed underneath the baseplate. The sensor layer consists of an electronic sensor system that continuously detects moisture and output leakage underneath the baseplate. A transmitter connected to the sensor layer continuously evaluates the incoming information and sends a status to a smartphone software application, which based on a predefined flow decides which information to deliver to the user about the baseplate status.

The overall aim of this clinical investigation is to evaluate the benefits of the new supporting product, Heylo compared to Standard of Care.

Read the detailed description

The Investigational device - Heylo, is already CE-marked.

The investigation is an open-labelled, randomized cross-over trial with two test periods evaluating Heylo and Standard of Care.

In total 144 subjects having an ileostomy or an colostomy will be included and randomized.

Being tested
Heylo, Standard of Care

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • HeyloDevice

    Heylo is used in combination with the ostomy baseplate usually used by the subjects. It will detect and notify the subject of the occurrence of output leakage under an ostomy baseplate.

  • Standard of CareDevice

    Standard of Care is the ostomy products (baseplate and bag) that the subject normally uses

Study groups in NCT05200416
Study groupRoleWhat they receive
Test Product - HeyloExperimentalThe arm includes the test product Heylo
Receives: Device: Heylo; Device: Standard of Care
Standard of CareActive comparatorThe arm includes Standard of Care
Receives: Device: Heylo; Device: Standard of Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Emotional Impact Score (Scale From 0-100)

    Measured by the validated OLI scale evaluated at the end of each test period. The questionnaire regarding Emotional impact contains 10 questions where the 4 answer options are: All of the time, Often, Sometimes and Rarely or never, which can be converted into a combined numerical score. The scale ranges from 0-100, where a score of 100 equals no impact and a score of 0 represents full impact.

    Measured: 8 weeks

Secondary outcomes (1)
  1. Participation in Society Domain Score (Scale From 0-100)

    Measured by WHODAS 2.0 evaluated at the end of each test period. The questionnaire regarding Participation in society contains 11 questions where the 5 answer options are: None, Mild, Moderate, Severe and Extreme or cannot do, which can be converted into a combined domain score. Each domain has a range of 0-100, where low scores equal better health and high scores indicate greater disability.

    Measured: 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jan 2022
  2. Study start13 Jan 2022
  3. Primary completion4 Nov 2022
  4. Study completion4 Nov 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
144 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05200416
Sponsor's protocol ID
CP345
Status last verified
Dec 2024
First submitted
7 Jan 2022
Last updated
23 Jan 2025
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Ambe PC, Brunckhorst E, Hansen HD, Gotfredsen JL, Vestergaard M, Ajslev TA. Effect of a Novel Digital Leakage Notification System (Heylo) for Ostomy Care on Quality of Life and Burden of Living With an Intestinal Ostomy: The ASSISTER Trial, A Randomized Controlled Cross-Over Trial. Mayo Clin Proc Digit Health. 2023 Sep 1;1(3):438-449. doi: 10.1016/j.mcpdig.2023.06.013. eCollection 2023 Sep.

    PubMed 40206623

Questions about this trial

What is this clinical trial studying?

A study testing Heylo in people with Ileostomy - Stoma and Colostomy Stoma, run by Coloplast A/S at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Jan 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Emotional Impact Score (Scale From 0-100) (time frame: 8 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05200416, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in